As featured in
Documented Client Outcomes // 2019–2025
$2.4B in client revenue growth since 2019.
We engineer market access strategies and pipeline commercialization plans for mid-cap pharma companies navigating the distance between Phase III approval and profitable launch. The numbers above are audited. The methodology is proprietary. The conversation is confidential.
Client Revenue Growth Since 2019
Specialty Pharma Engagements
Clients Achieve Peak Sales Within 24 Months
Therapeutic Areas
Recovering formulary position for a branded CDK4/6 inhibitor losing ground to a generic entrant.
A mid-cap oncology firm with a single approved molecule watched preferred tier status erode across three national PBMs within eight months of a competitor's generic entry. Revenue trajectory had inflected downward. The clinical differentiation story existed but had never been operationalized for payer audiences.
Preferred tier status lost across Caremark, Express Scripts, and OptumRx within 8 months.
The commercial team had a strong clinical narrative but lacked a payer-specific value framework that translated Phase III outcomes data into formulary positioning language. The HEOR package was designed for KOL engagement, not P&T committee submissions. Rebate strategy was reactive rather than structured. The molecule had 14 months to stabilize market share before the next competitor NDA filing.
Pricing architecture redesign, KOL sequencing, and a payer negotiation framework built around real-world evidence.
We reconstructed the value dossier from the payer perspective — reframing OS data as total cost-of-care reduction and mapping adherence metrics to per-member-per-month projections. A KOL engagement sequence was designed to generate independent clinical commentary before the next P&T cycle. A tiered rebate model was built that protected net price while enabling preferred placement at two of three national PBMs.
Preferred tier status recovered at two PBMs. Market share stabilized 14 months ahead of the competitor NDA.
Formulary tier recovery was achieved at Express Scripts and OptumRx within 14 months. Net price erosion was contained to 6.2% vs. a modeled 18% under the prior trajectory. The real-world evidence publication generated by the KOL engagement program became a reference document in the competitor's P&T review cycle.
Formulary tier recovery vs. baseline trajectory
Net price erosion vs. modeled −18%
Ahead of competitor NDA stabilization
National PBM negotiations concluded
"The value dossier they built was the first document our medical affairs team and payer team had ever agreed on. That alignment changed the negotiation dynamic entirely."
— VP Commercial Operations, undisclosed oncology firm — from 2023 Annual Report commentary
Accelerating time-to-peak sales across a two-molecule rare disease portfolio with competing launch timelines.
A specialty pharma firm with orphan drug designations for two molecules in adjacent rare disease indications faced a sequencing problem: launching both within 18 months would fragment commercial infrastructure and confuse payer positioning. Launching sequentially risked losing first-mover advantage in the second indication.
Two molecules, two launch windows 11 months apart, one commercial team, and a CFO preparing for a Series C roadshow.
The firm had modeled both launches independently. The combined revenue model used in the investor deck assumed peak penetration rates that were inconsistent with each other — the second molecule's projections had been built using the first molecule's patient identification infrastructure, which wouldn't exist at launch. The CFO needed a model that would survive due diligence. The CEO needed a launch sequence that wouldn't cannibalize either asset.
An integrated portfolio commercialization architecture with shared patient services infrastructure and staggered payer engagement timelines.
We rebuilt the revenue model from patient flow first — mapping diagnosis rates, time-to-treatment initiation, and specialist concentration by geography. A shared patient services platform was designed that served both molecules without requiring duplicate infrastructure. Payer engagement was sequenced so that the first molecule's formulary negotiations established coverage precedent that the second molecule could leverage. The investor model was rebuilt with conservative, defensible assumptions and a sensitivity table the CFO could use in Q&A.
Series C closed at target valuation. First molecule reached peak sales in 19 months. Second molecule launched on schedule with pre-negotiated coverage.
The Series C closed within 60 days of the roadshow at the target valuation. The first molecule reached peak sales penetration in 19 months — 8 months ahead of the original model. The shared patient services infrastructure reduced commercial launch costs for the second molecule by $4.2M. Pre-negotiated payer coverage for the second indication was secured before first patient treated.
Peak revenue acceleration vs. baseline model
Time-to-peak for Molecule A (−8 months vs. plan)
Saved on second launch infrastructure
Closed at target valuation within 60 days
"Every assumption in that model had a citation. When the lead investor's diligence team came back with questions, we had the source data in a folder. That was the first time I'd seen a pharma revenue model survive a real due diligence process."
— CFO, undisclosed rare disease firm — from Series C investor materials, 2024
Entering six European biosimilar markets simultaneously without triggering a reference product price erosion cascade.
A biosimilar entrant with an approved anti-TNF molecule faced a pricing corridor problem: aggressive entry pricing in Germany would establish an IRP reference price that would depress net pricing in France, Italy, and Spain before the first patient was treated in those markets. The standard playbook — price low, gain volume — would destroy the portfolio's 5-year revenue model.
IRP linkage across six markets meant that German launch pricing would set a ceiling for the entire European portfolio.
The commercial team had been advised to price the German launch at a 30% discount to the reference product — standard biosimilar entry logic. Our analysis showed that this would trigger IRP adjustments in France within 90 days and in Italy and Spain within 180 days, reducing the portfolio's 5-year net revenue projection by €180M. The molecule had clinical data supporting a narrower discount. The question was whether the payer environment would accept it.
A sequenced market entry architecture with differentiated pricing by tender structure, IRP modeling, and a clinical differentiation strategy for high-volume therapeutic areas.
We mapped the IRP linkage network across all six markets and identified that Austria and the Netherlands — both with lower IRP reference weights — could absorb a narrower discount without triggering cascades in anchor markets. A sequenced entry plan was built: Netherlands and Austria first at 18% discount, Germany second at 22% with a managed entry agreement structure that kept net price opaque to IRP calculations, France and Italy third with the German MEA as precedent. Clinical differentiation messaging was built around subcutaneous formulation data to justify the narrower discount in P&T submissions.
Six-market entry completed without triggering IRP cascade. Portfolio net price held 11 percentage points above the original model.
The sequenced entry architecture held. German MEA structure was accepted by GBA. IRP cascade to France and Italy was contained — net price in both markets came in 11 percentage points above the original 30%-discount model. Portfolio 5-year net revenue was preserved at €340M vs. the €160M projection under the original strategy. The clinical differentiation program generated two independent health technology assessment submissions that are now being used as templates by the firm's pipeline team.
Revenue preserved vs. original entry strategy
Net price above original 30% discount model
Markets entered without IRP cascade
HTA submissions now used as pipeline templates
"We came in thinking biosimilar entry was a volume game. They showed us it was a sequencing game. That reframe changed the entire commercial strategy for the next three molecules in the pipeline."
— CEO, undisclosed biosimilar entrant — from board presentation, Q3 2024
Confidential Engagement
Request a Confidential Assessment
We read your 10-K before we respond. The brief you submit here initiates a structured review of your commercialization position — not a sales call.
Research Publication // 2024
2024 Specialty Pharma Commercialization Benchmark
Pricing corridor analysis across 47 specialty launches. Time-to-peak benchmarks by therapeutic area. Payer mix modeling for single-indication vs. portfolio molecules. Used by 12 VP-level commercial teams in 2024 investor roadshow preparation.
Launches Analyzed
VP Teams Used
Data Year